Collagen Solutions Plc

Transcription

1 Collagen Solutions Plc Jamal Rushdy, CEO Growth & Innovation Forum 2017 January 2017

2 Disclaimer This presentation is incomplete without reference to, and should be viewed solely in conjunction with the oral briefing which accompanies it. The information in this presentation is subject to updating, revision and amendment. The information in this presentation, which includes certain information drawn from public sources does not purport to be comprehensive and has not been independently verified. This presentation has not been examined, reviewed or compiled by the Company s independent certified accountants. No reliance may be placed for any purpose whatsoever on the information contained in this presentation or any assumptions made as to its completeness. No representation or warranty, express or implied, is given by the Company, any of its subsidiaries or any of its advisors, directors, officers, employees or agents, as to the accuracy, reliability or completeness of the information or opinions contained in this presentation or in any revision of the presentation or of any other written or oral information made or to be made available to any information or opinions (which should not be relied upon) and no responsibility is accepted for any errors, misstatements in or omissions from this presentation or for any loss howsoever arising, directly or indirectly, from any use of this presentation or its contents. The information and opinions contained in this presentation are provided as at the date of this presentation and are subject to change without notice. In particular, this presentation may contain certain forward looking statements that are subject to the usual risk factors. Whilst the Company believes the expectations reflected herein to be reasonable in light of the information available to them at this time, the actual outcome may be materially different owing to factors beyond the Company s control or with in the Company s control where, for example the Company decides on a change of strategy. Accordingly no reliance may be placed on the figures or other indications contained in any such potential forward-looking statements. No representation or warranty of any kind is made with respect to the accuracy or completeness of the financial projections or other forward looking statements, any assumptions underlying them, the future operations or the amount of any future income or loss. The content of this presentation has not been approved by an authorised person within the meaning of the Financial Services and Markets Act 2000 ( FSMA ). This presentation does not constitute or form part of any offer or invitation to see, or any solicitation of any offer to purchase or subscribe for or otherwise acquire, any securities in the Company in any jurisdiction or any other body corporation or an invitation or an inducement to engage in investment activity under section 21 of FSMA, nor shall it or any part of it form the basis of or be relied on in connection with any contract therefore. This presentation does not constitute an invitation to effect any transaction with the Company or to make use of any services provided by the Company. Reliance on the information contained in this presentation for the purposes of engaging in any investment activity may expose the investor to a significant risk of losing all of the property or assets invested. Any person who is in any doubt about the investment to which this presentation relates should consult a person duly authorised for the purposes of FSMA who specialises in the acquisition of shares and other securities. By attending the presentation, or reading or accepting this document you agree to be bound by the foregoing limitations. January

3 Overview Opportunity Multiple growth initiatives create potential for 5x+ revenue within 5 years Market $1.5bn+ biomaterials market opportunity growing 10%+ Core Business Stable recurring sales from collagen and tissue-based biomaterials and devices Finished Device Pipeline Pipeline of finished devices with owned I.P. for commercialisation via distribution and licensing Growth Recently reported 6 month interim results 1.9m sales/other income, +30% on prior year 3

4 Core Business Products & Services Medical Grade Collagen Pericardium & Other Tissues OEM & Development Services Research & tissue engineering Dental membranes Cartilage scaffolds Heart valves Soft tissue mesh Wound scaffolds Bone graft substitutes Cell therapy carriers 4

5 Stable Global Core Business Set for Growth Core Business Growth Model Development and prototypes to supply and manufacturing Revenue is sticky Switching costs are high New commercial team and distribution Geographically expand Current customer base demographics USA, Canada, Northern Europe, Middle East, South Korea Diverse mix from early/pre-revenue to $1B+ Applications in orthopaedics, cardiovascular, wounds, dental, research, and tissue engineering 5

6 Finished Device Pipeline ChondroMimetic Cartilage Repair Fibrillar Collagen Wound Treatment Bone Graft Substitutes Bone Regeneration Previously used in Europe, 6+ years evidence in patients Retro study and CE mark in process, targeted for 1H 2017 Potential to address multiple markets in wound care and burns Target wound market clearance in 2018 Provisional patent filed December, 2016 Target orthopaedic market clearance in

7 ChondroMimetic Osteochondral Plug Scaffold for treatment of cartilage defects Highlights Chondral layer: collagen/glycosaminoglycan Osseous layer: collagen/glycosaminoglycan/ calcium phosphate Addresses clinical need for clinically and cost effective alternative to current standards of care ChondroMimetic advantages: Single surgery Cost effective Address both cartilage and underlying bone Previously used in Europe, 6+ years evidence in patients Retro study and CE mark for OUS launch in process, targeted for 1H 2017 Enhanced MRI image from original pilot study showing 10 day and 6 month results. 7

8 Multiple Growth Drivers 5x FY 2014 FY 2015 FY 2016 FY 2017 Sales and other income (millions) 6 Mos Full Year Sales channels, geographic expansion, OEM mix Current finished device pipeline + licensing/distribution Next stage pipeline + licensing/distribution 8

9 Summary Strategy addresses a significant opportunity $1.5bn+ biomaterials opportunity Core supply and development business to grow through focused execution Stable core business, embedded revenue Pipeline of owned products for license and distribution Cartilage, bone, wounds Commercial and R&D investments for sustainable growth Goal of 5x sales in 5 years 9

10 Our Vision To become the industry s first choice for regenerative biomaterials 10

11 Thank You

12 Appendix: Six months ended 30 September 2016 Financial KPIs Gill Black, CFO 12

13 Embedded customers driving revenue growth 1.04m Year Ending 31 March m Year Ending 31 March Mar Sep Mar Sep Mar Sep-16 Six month revenue & other income trend 13

14 Financial KPIs Revenue & Other Income ( ) Gross Profit ( ) Gross Margin (%) 1,460,218 1,891,001 1,090,856 1,305, % 75.7% 143, , % 30-Sep Sep Sep Sep Sep Sep Sep Sep Sep-16 14

15 Financial KPIs LBITDA* ( ) 30-Sep Sep Sep-16 (79,376) EPS (p) 30-Sep Sep Sep-16 (0.26) Cash and Equivalents ( ) 3,104,230 (522,144) (0.60) 1,657,193 (712,537) (0.88) 927,094 *Before separately identifiable items: 30-Sep Sep Sep : Unrealised translation losses on deferred consideration - 294,229 debit 2015: NIL 2014: NIL 15

16 Revenue by geographic region 6 months ended 30 September 2016 Revenue by region 2015 Revenue by region 36% 54% 39% 59% 10% 2% North America EMEA Asia Pacific North America EMEA Asia Pacific 16

17 Revenue by activity 6 months ended 30 September 2016 Revenue by activity 2015 Revenue by activity 35% 29% 7% 58% 7% 64% Contract Manufacturing Development Materials Contract Manufacturing Development Materials 17